Suppr超能文献

使用非维生素 K 拮抗剂口服抗凝剂的心房颤动患者的 HAS-BLED、ATRIA 和 ORBIT 出血评分。

The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants.

机构信息

Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Denmark; Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom.

Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Denmark; Unit for Clinical BiostatisticsAalborg University Hospital, Denmark.

出版信息

Am J Med. 2018 May;131(5):574.e13-574.e27. doi: 10.1016/j.amjmed.2017.11.046. Epub 2017 Dec 21.

Abstract

BACKGROUND

Various bleeding risk scores have been proposed to assess the risk of bleeding in patients with atrial fibrillation taking oral anticoagulants. Limited data are available with these scores, in users of non-vitamin K antagonist oral anticoagulants.

METHODS

Using the Danish registries, we evaluated and compared the risk classification properties of the Hypertension, Age, Stroke, Bleeding tendency/predisposition, Labile international normalized ratios, Elderly age/frailty, Drugs such as concomitant aspirin/nonsteroidal anti-inflammatory drugs or alcohol excess (HAS-BLED), Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA), and Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT) scores for predicting major bleeding in 57,930 atrial fibrillation patients (44.6% female; mean age 73.5 years, standard deviation 11.4 years; mean CHADS-VASc score 3.2, standard deviation 1.8).

RESULTS

At 1-year follow-up, C-statistics for ATRIA, HAS-BLED, and ORBIT were approximately 0.59, with only minor differences between scores. Both ATRIA and ORBIT categorized more patients as "low risk" (both >83%, when compared with HAS-BLED, only 53%), and qualitatively, the receiver operating characteristic curves revealed higher sensitivity (62.8%) for HAS-BLED compared with ATRIA (29.7%) and ORBIT (37.1%). The clinical usefulness of scores was evaluated using decision curve analyses at a 1-year perspective. If the intervention threshold is low (<1.7%), the benefit is toward monitoring all patients. If preference is for a major bleeding risk threshold between 1.7% and 2.0%, most benefit was obtained by using HAS-BLED. The ORBIT and ATRIA scores provided better benefit for thresholds between 2.0% and 6.0%.

CONCLUSION

This analysis of contemporary bleeding risk score stratification in a "real-world" non-vitamin K antagonist oral anticoagulant users population with atrial fibrillation showed modest predictive values using C-statistics. The scores represent different risk thresholds, with HAS-BLED classifying least patients at low risk and achieving the highest benefit if applying a major bleeding intervention threshold of approximately 2%, whereas benefit from using either ATRIA score or ORBIT score was only evident using higher intervention thresholds.

摘要

背景

各种出血风险评分已被提出,用于评估服用口服抗凝剂的房颤患者出血风险。然而,这些评分在使用非维生素 K 拮抗剂口服抗凝剂的患者中,相关数据有限。

方法

我们利用丹麦的登记处,评估和比较了高血压、年龄、中风、出血倾向/倾向、不稳定的国际标准化比值、老年/虚弱、同时使用阿司匹林/非甾体抗炎药或酒精过量的药物(HAS-BLED)、抗凝和房颤危险因素(ATRIA),以及房颤更好信息治疗的结果登记(ORBIT)评分在预测 57930 例房颤患者(44.6%为女性;平均年龄 73.5 岁,标准差 11.4 岁;平均 CHADS-VASc 评分为 3.2,标准差 1.8)的大出血风险方面的风险分类性能。

结果

在 1 年随访时,ATRIA、HAS-BLED 和 ORBIT 的 C 统计量约为 0.59,评分之间仅有微小差异。与 HAS-BLED 相比,ATRIA 和 ORBIT 将更多患者归类为“低风险”(均>83%,而 HAS-BLED 仅为 53%),并且定性地,ROC 曲线显示 HAS-BLED 比 ATRIA(29.7%)和 ORBIT(37.1%)具有更高的敏感性。在 1 年的时间内,通过决策曲线分析评估了评分的临床应用价值。如果干预阈值较低(<1.7%),则监测所有患者的效果较好。如果更倾向于将大出血风险阈值设定在 1.7%至 2.0%之间,则使用 HAS-BLED 效果最佳。ORBIT 和 ATRIA 评分在 2.0%至 6.0%的阈值下提供更好的获益。

结论

本研究对非维生素 K 拮抗剂口服抗凝剂房颤患者的当代出血风险评分分层进行了分析,使用 C 统计量显示出了中等的预测价值。这些评分代表了不同的风险阈值,HAS-BLED 将最少的患者归类为低风险,如果将大出血干预阈值设定在约 2%左右,其获益最大,而使用 ATRIA 评分或 ORBIT 评分的获益仅在使用较高的干预阈值时才明显。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验